Cargando…

Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment

In this research, KLA-modified liposomes co-loaded with 5-fluorouracil and paclitaxel (KLA-5-FU/PTX Lps) were developed, and their antitumor activity against triple-negative breast cancer (TNBC) was evaluated. KLA-5-FU/PTX Lps were prepared using the thin-film dispersion method, and their in vitro a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Tianyu, Chen, Hui, Jiang, Yichun, Yan, Qi, Zheng, Shuling, Wu, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318860/ https://www.ncbi.nlm.nih.gov/pubmed/35890181 http://dx.doi.org/10.3390/ph15070881

Ejemplares similares

Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides
por: Sun, Jiawei, et al.
Publicado: (2017)

Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
por: Wang, Zhongjie, et al.
Publicado: (2023)

Lysine lactylation (Kla) might be a novel therapeutic target for breast cancer
por: Deng, Jian, et al.
Publicado: (2023)

Enhanced Therapeutic Effect of Optimized Melittin-dKLA, a Peptide Agent Targeting M2-like Tumor-Associated Macrophages in Triple-Negative Breast Cancer
por: Kim, Soyoung, et al.
Publicado: (2022)

Co-encapsulation of paclitaxel and 5-fluorouracil in folic acid-modified, lipid-encapsulated hollow mesoporous silica nanoparticles for synergistic breast cancer treatment
por: Yin, Huanli, et al.
Publicado: (2022)

Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity
por: Hao, Wenjing, et al.
Publicado: (2019)

Safety evaluation of the food enzyme β‐galactosidase from the genetically modified Kluyveromyces lactis strain KLA
por: Lambré, Claude, et al.
Publicado: (2022)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
por: Si, Yingnan, et al.
Publicado: (2021)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

Antitumor Actions of Intratumoral Delivery of Membrane-Fused Mitochondria in a Mouse Model of Triple-Negative Breast Cancers
por: Chang, Jui-Chih, et al.
Publicado: (2020)

Therapeutic Effect of Melittin–dKLA Targeting Tumor-Associated Macrophages in Melanoma
por: Han, Ik-Hwan, et al.
Publicado: (2022)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

Engineering Remotely Triggered Liposomes to Target Triple Negative Breast Cancer
por: Sneider, Alexandra, et al.
Publicado: (2017)

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2018)

Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer
por: Chen, Yi-Qing, et al.
Publicado: (2021)

Rietveld refinement of KLaTiO(4) from X-ray powder data
por: Zhu, Bai-Chuan, et al.
Publicado: (2011)

Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis
por: Guo, Peng, et al.
Publicado: (2019)

Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics
por: Kommineni, Nagavendra, et al.
Publicado: (2022)

Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy
por: Zhao, Heng, et al.
Publicado: (2023)

Effective in vitro delivery of paclitaxel by nanocargo of mesoporous polycaprolactone against triple negative breast cancer cells by minimalizing drug dose
por: Medhi, Himadri, et al.
Publicado: (2020)

Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer
por: Guo, Beibei, et al.
Publicado: (2023)

HIF and COX-2 expression in triple negative breast cancer cells with hypoxia and 5-fluorouracil
por: Mori, Noriko, et al.
Publicado: (2020)

Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model
por: Price, Lauren S.L., et al.
Publicado: (2021)

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer
por: Fu, Bo, et al.
Publicado: (2015)

Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer
por: Ding, Yinan, et al.
Publicado: (2021)

Triphenylphosphonium-modified mitochondria-targeted paclitaxel nanocrystals for overcoming multidrug resistance
por: Han, Xue, et al.
Publicado: (2019)

Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer
por: Jin, Xin, et al.
Publicado: (2020)

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines
por: Berruti, A, et al.
Publicado: (2005)

The anticancer efficacy of paclitaxel liposomes modified with low-toxicity hydrophobic cell-penetrating peptides in breast cancer: an in vitro and in vivo evaluation
por: Zhang, Qi, et al.
Publicado: (2018)

Lipids with negative spontaneous curvature decrease the solubility of the cancer drug paclitaxel in liposomes
por: Steffes, Victoria, et al.
Publicado: (2023)

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer
por: Liu, Xi-Yu, et al.
Publicado: (2020)

Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention
por: Wang, Hongkun, et al.
Publicado: (2020)

Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer
por: Napier, Tiara S., et al.
Publicado: (2023)

A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer
por: Chen, Chuanrong, et al.
Publicado: (2021)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g6nemn03j2nru1t2qepoufb6ve